Therapy Areas: Respiratory
Henley Ion develops protective device against airborne SARS-CoV-2 and emerging variants
13 January 2022 -

Life sciences company Henley Ion on Wednesday received positive testing results from its protective device designed for respiratory protection, without the use of conventional filtration that makes breathing difficult, against airborne SARS-CoV-2 and emerging variants.

Based on initial testing with the company's first prototype at high-containment laboratory located at the Tulane National Primate Research Center, the Henley Ion Virus Defender removed >99% of SARS-CoV-2 bioaerosols under rigorous Biosafety Level 3 testing conditions.

The company's co-founder Dr Julian Henley is the brain behind the patent-pending Henley Ion Virus Defender technology that uses micronized electrostatic precipitation (mEP) to remove infectious bioaerosols from the air. The respirator device uses mEP directly integrated into the mask to effectively remove infectious aerosol particles from both inhaled and exhaled air - as opposed to filtration.

A published paper with peer-reviewable performance data is expected to be released by the company in the future.

In conjunction, the company's team designed and engineered the mEP for easy integration into existing personal protective equipment (PPE) and safety equipment. It has been designed to augment respirators, military and emergency response helmets and other safety equipment, with the core technology serving as the primary or adjunctive mechanism of respiratory protection.



Related Headlines